Investigation into the Impact of Proton Pump Inhibitors on Sertraline Transport across the Blood-Brain Barrier
In this study, PPIs were further found to inhibit the mRNA and protein expression of brain BCRP. To sum up, the findings of this study revealed that PPIs could enhance the brain distribution and antidepressant effect of sertraline, which may be attributed to the inhibition of BCRP expression at the BBB by PPIs.PMID:38006986 | DOI:10.1016/j.ejps.2023.106653 (Source: European Journal of Pharmaceutical Sciences)
Source: European Journal of Pharmaceutical Sciences - November 25, 2023 Category: Drugs & Pharmacology Authors: Yumeng Xiao Wenwen Xu Dandan Niu Zhuowei Quan Ling Wang Source Type: research
Challenges in Conducting Clinical Trials for Preeclampsia
AbstractPurpose of ReviewTo review recent data describing the challenges and innovations in therapeutic research focused on the prevention and treatment of preeclampsia.Recent FindingsPregnant individuals have traditionally been excluded from therapeutic research, resulting in a paucity of innovation in therapeutics for pregnancy-specific medical conditions, especially preeclampsia. With the increased awareness of maternal morbidity and mortality, there is significant interest among researchers to expand therapeutic research in pregnancy. Several medications, including aspirin, pravastatin, metformin, and esomeprazole, whi...
Source: Current Hypertension Reports - November 16, 2023 Category: Primary Care Source Type: research
Infections associated with clozapine: a pharmacovigilance study using VigiBase ®
Discussion: Our study revealed a significant safety signal between clozapine use and infections, predominantly respiratory and gastrointestinal infections. The co-administration of clozapine with valproic acid or proton pump inhibitors may potentially contribute to an increased risk of infection. Further vigilance is warranted in clinical practice, and consideration of therapeutic drug monitoring of clozapine in cases involving concomitant use of these drugs or in the presence of infections may be beneficial. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - October 2, 2023 Category: Drugs & Pharmacology Source Type: research
Association Study of Esomeprazole Pharmacokinetics and CYP2C19 Gene Polymorphisms
AbstractTo investigate the association between esomeprazole pharmacokinetics andCYP2C19 gene polymorphisms in a cohort of 95 healthy Chinese participants. A cohort of 95 participants was assembled and stratified into 2 distinct groups, receiving either 20 or 40 mg of esomeprazole through oral administration. The subjects encompassed 17 poor metabolizers, 47 intermediate metabolizers, and 31 rapid metabolizers, and their genotypes were ascertained using the polymerase chain reaction–restriction fragment length polymorphism technique. Esomeprazole plasma concentrations were quantified employing a high-performance liquid ...
Source: Clinical Pharmacology in Drug Development - September 30, 2023 Category: Drugs & Pharmacology Authors: Yuan Fang,
Xia He,
Ai Peng,
Yi qi Yang,
Jin Xiang Tags: Original Article Source Type: research
Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view
World J Cardiol. 2023 Aug 26;15(8):375-394. doi: 10.4330/wjc.v15.i8.375.ABSTRACTAspirin, other antiplatelet agents, and anticoagulant drugs are used across a wide spectrum of cardiovascular and cerebrovascular diseases. A concomitant proton pump inhibitor (PPI) treatment is often prescribed in these patients, as gastrointestinal complications are relatively frequent. On the other hand, a potential increased risk of cardiovascular events has been suggested in patients treated with PPIs; in particular, it has been discussed whether these drugs may reduce the cardiovascular protection of clopidogrel, due to pharmacodynamic an...
Source: World Journal of Cardiology - September 29, 2023 Category: Cardiology Authors: Maurizio Giuseppe Abrignani Alberto Lombardo Annabella Braschi Nicol ò Renda Vincenzo Abrignani Source Type: research
Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view
World J Cardiol. 2023 Aug 26;15(8):375-394. doi: 10.4330/wjc.v15.i8.375.ABSTRACTAspirin, other antiplatelet agents, and anticoagulant drugs are used across a wide spectrum of cardiovascular and cerebrovascular diseases. A concomitant proton pump inhibitor (PPI) treatment is often prescribed in these patients, as gastrointestinal complications are relatively frequent. On the other hand, a potential increased risk of cardiovascular events has been suggested in patients treated with PPIs; in particular, it has been discussed whether these drugs may reduce the cardiovascular protection of clopidogrel, due to pharmacodynamic an...
Source: World Journal of Cardiology - September 29, 2023 Category: Cardiology Authors: Maurizio Giuseppe Abrignani Alberto Lombardo Annabella Braschi Nicol ò Renda Vincenzo Abrignani Source Type: research
Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view
World J Cardiol. 2023 Aug 26;15(8):375-394. doi: 10.4330/wjc.v15.i8.375.ABSTRACTAspirin, other antiplatelet agents, and anticoagulant drugs are used across a wide spectrum of cardiovascular and cerebrovascular diseases. A concomitant proton pump inhibitor (PPI) treatment is often prescribed in these patients, as gastrointestinal complications are relatively frequent. On the other hand, a potential increased risk of cardiovascular events has been suggested in patients treated with PPIs; in particular, it has been discussed whether these drugs may reduce the cardiovascular protection of clopidogrel, due to pharmacodynamic an...
Source: World Journal of Cardiology - September 29, 2023 Category: Cardiology Authors: Maurizio Giuseppe Abrignani Alberto Lombardo Annabella Braschi Nicol ò Renda Vincenzo Abrignani Source Type: research
Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view
World J Cardiol. 2023 Aug 26;15(8):375-394. doi: 10.4330/wjc.v15.i8.375.ABSTRACTAspirin, other antiplatelet agents, and anticoagulant drugs are used across a wide spectrum of cardiovascular and cerebrovascular diseases. A concomitant proton pump inhibitor (PPI) treatment is often prescribed in these patients, as gastrointestinal complications are relatively frequent. On the other hand, a potential increased risk of cardiovascular events has been suggested in patients treated with PPIs; in particular, it has been discussed whether these drugs may reduce the cardiovascular protection of clopidogrel, due to pharmacodynamic an...
Source: World Journal of Cardiology - September 29, 2023 Category: Cardiology Authors: Maurizio Giuseppe Abrignani Alberto Lombardo Annabella Braschi Nicol ò Renda Vincenzo Abrignani Source Type: research
Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view
World J Cardiol. 2023 Aug 26;15(8):375-394. doi: 10.4330/wjc.v15.i8.375.ABSTRACTAspirin, other antiplatelet agents, and anticoagulant drugs are used across a wide spectrum of cardiovascular and cerebrovascular diseases. A concomitant proton pump inhibitor (PPI) treatment is often prescribed in these patients, as gastrointestinal complications are relatively frequent. On the other hand, a potential increased risk of cardiovascular events has been suggested in patients treated with PPIs; in particular, it has been discussed whether these drugs may reduce the cardiovascular protection of clopidogrel, due to pharmacodynamic an...
Source: World Journal of Cardiology - September 29, 2023 Category: Cardiology Authors: Maurizio Giuseppe Abrignani Alberto Lombardo Annabella Braschi Nicol ò Renda Vincenzo Abrignani Source Type: research
